NíoSync unlocks innovation for patients by launching clinically proven therapies across European markets. Our scalable commercial platform solves the regulatory and reimbursement complexity that would otherwise prevent life-changing medicines from reaching the patients who need them.
European markets, each with its own pricing, reimbursement and regulatory requirements
Years of combined leadership experience across life sciences
Of globally approved medicines never launch in EuropeEFPIA Patients W.A.I.T. Indicator 2024
01 · Why We Exist
Thousands of patients across Europe wait for medicines that are already approved, clinically proven and available elsewhere in the world.
More than half of globally approved medicines never launch in Europe. Not because the science fails, but because fragmented pricing, reimbursement and health technology assessment processes make broad launch economics difficult, especially in smaller markets. One EMA approval does not mean one European launch — it means the start of multiple separate negotiations, each required before a single patient is reached.
NíoSync was built to close that gap: combining deep European market expertise with a scalable commercial platform to give biopharma innovators a viable path into Europe, and give European patients access to the therapies they need.
Separate pricing, reimbursement and HTA systems across the EU, each negotiated independently before a single patient is reached.
One EMA approval ≠ one European launch.
02 · What We Do
We have a singular focus: closing the gap between medical innovation and the patients who need it most.
We secure the rights to clinically proven specialty medicines from biopharma companies seeking a trusted, capital-efficient partner for European commercialisation, focusing on therapies with clear unmet need and an established clinical profile.
We build the regulatory, market access and commercial infrastructure to launch and grow specialty therapies across Europe's key markets, handling the complexity so medicines move from approval to patient as efficiently as possible.
We work with healthcare systems, providers, payers and patient communities to ensure the right patients receive the right treatments at the right time. Patient access is the measure of our success.
03 · Our Platform
Bringing a new medicine to European patients means navigating a complex regulatory and commercial landscapes. NíoSync operates through a network of established European partners, combining local market intelligence with the scale to move decisively across multiple markets at once.
EMA and national authority engagement across EU markets.
HTA strategy, reimbursement and payer negotiations.
Pan-European supply chain via established partner networks.
KOL engagement and clinical evidence communication.
04 · Team
Co-Founder & Managing Director
Neil has over two decades of leadership experience across life sciences, health technology and software, most recently as Chief Commercial Officer at Datalex plc and previously Chief Operating Officer at Malin plc. He spent a decade at Elan plc and is a Barrister and Fellow of the Chartered Governance Institute.
Co-Founder & Managing Director
Harm brings over 20 years of expertise in strategy and corporate finance in life sciences, including strategic planning roles at Alkermes and Elan. He holds an MSc in Management & Organisation from Rijksuniversiteit Groningen and a Trinity College MBA, and is an IoD certified director.
General Manager, Commercial & Alliances
Ciarán brings over 15 years of commercial leadership and international development experience in consumer health, including roles as UK Commercial Director and Ireland Sales Director at Reckitt Benckiser.
Head of External Operations
Donal brings 25 years of biopharma operations experience as a supply chain and procurement leader. He is Six Sigma Black Belt certified, with extensive operational excellence experience across small and large molecule platforms.
05 · Partner With Us
If you have a clinically proven specialty medicine ready for European patients, NíoSync offers the most capital-efficient route to market available. We remove the need to build European commercial infrastructure from scratch, providing a single, experienced partner who can take your medicine from regulatory approval to patient access across multiple markets simultaneously.
We are actively seeking partnerships across
